Inverness Counsel’s Edwards Lifesciences EW Stock Holding History

Inverness Counsel’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.52M	Buy	18,342 +1,241	+7%	+$119K	0.08%	72
2022 Q2	$1.63M	Sell	17,101 -157	-0.9%	-$16.3K	0.09%	63
2022 Q1	$2.03M	Buy	17,258 +8,537	+98%	+$958K	0.09%	63
2021 Q4	$1.13M	Sell	8,721 -4,055	-32%	-$473K	0.04%	80
2021 Q3	$1.45M	Buy	12,776 +5,511	+76%	+$629K	0.05%	76
2021 Q2	$752K	Buy	+7,265	New	+$685K	0.03%	96
2017 Q2	–	Sell	-7,755	Closed	-$242K	–	93
2017 Q1	$242K	Sell	7,755 -94,356	-92%	-$2.95M	0.02%	84
2016 Q4	$3.34M	Sell	102,111 -259,629	-72%	-$8.41M	0.25%	57
2016 Q3	$14.5M	Sell	361,740 -136,320	-27%	-$5.13M	1.14%	34
2016 Q2	$16.6M	Buy	498,060 +58,275	+13%	+$1.99M	1.29%	33
2016 Q1	$12.9M	Buy	+439,785	New	+$12.1M	1%	36

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Inverness Counsel's EW Position: Q3 2022 in Review

Inverness Counsel increased its Edwards Lifesciences (EW) stake by 7.3% in Q3 2022, buying an estimated $119K and bringing the position to 18,342 shares worth $1.52M. The position accounts for 0.08% of the portfolio, ranked #72.

Inverness Counsel first reported a position in EW in Q1 2016 and has held it in 11 quarters since. The position peaked at $16.6M in Q2 2016. 1,247 funds tracked by Wall St. Rank hold EW as of Q3 2022.

Inverness Counsel held 18,342 shares of Edwards Lifesciences worth $1.52M as of Q3 2022.
Inverness Counsel bought 1,241 Edwards Lifesciences shares in Q3 2022, an estimated $119K.
Edwards Lifesciences made up 0.08% of Inverness Counsel's portfolio in Q3 2022, its #72 holding.
Inverness Counsel first reported a position in Edwards Lifesciences in Q1 2016 and has held it in 11 quarters since.
Inverness Counsel's Edwards Lifesciences position peaked at $16.6M in Q2 2016.
1,247 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2022.

Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.